Mesenchymal stem cell-derived exosomes and non-coding RNAs: Regulatory and therapeutic role in liver diseases

Wang, Cheng; Zhou, Honglin; Wu, Rui; Guo, Yuqin; Gong, Lihong; Fu, Ke; Ma, Cheng; Peng, Cheng; Li, Yunxia

doi:10.1016/j.biopha.2022.114040

Cited by 12 publications

(9 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On a different note, one may wonder whether there was any uptake of EVs by any organs after IV injections. Our previous studies have shown that there was significant hepatic uptake of EVs after IV administration; despite hepatic uptake after IV injection, there were no detectable differences in liver inflammation, fibrosis, or proliferation, which may be because this was not a liver disease model [7,8,14] . The main value of the negative hepatic findings is a grossly negative side effect profile to the liver tissue after IV HBMSC-EV injection, an increasingly common and noninvasive EV delivery method.…”

Section: Discussionmentioning

confidence: 98%

“…Furthermore, intramyocardial (IM) injection has been shown to be the most reliable form of EV delivery, while intravenous (IV) injection is not [1,2,[4][5][6][7] . A systemic review found that when EVs were intravenously injected, there was little to no evidence of EV localization to the heart, with primarily hepatic and splenic uptake [8] . We recently confirmed these findings in a model of murine acute MI, and only found cardiac uptake of EVs after IM injection and not with IV injection [7] .…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we delivered human bone mesenchymal stem cell-derived EVs (HBMSC-EV) via either IM or IV injection after murine acute MI and examined cardiac function 28 days post-injection. Additionally, as our previous findings confirmed hepatic HBMSC-EV uptake after IV injection, we evaluated for evidence of changes in liver inflammation, fibrosis, growth, and oxidative status 28 days post-injection since mesenchymal stem cell-derived EVs have been shown to have beneficial effects in preclinical liver disease models [ 9 ] . We also wanted to determine if there were any detectable long-term changes in the liver after HBMSC-EV uptake.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lack of cardiac benefit after intramyocardial or intravenous injection of mesenchymal stem cell-derived extracellular vesicles supports the need for optimized cardiac delivery

Xu,

Broadwin,

Faherty

et al. 2023

Vessel Plus

View full text Add to dashboard Cite

Aim: To determine the differences in improvement in cardiac function by intramyocardial (IM) vs. intravenous (IV) injection of human bone mesenchymal stem cell-derived extracellular vesicles (HBMSC-EV) after acute MI. Methods: FVB mice underwent acute MI via left anterior descending coronary artery ligation and subsequent injection of: (1) IM saline control; (2) IM HBMSC-EV; (3) IV saline control; and (4) IV HBMSC-EV. Cardiac function was evaluated with weekly postoperative echocardiography. On postoperative day 28, the mice were euthanized, and the heart, lungs, liver, spleen, and kidneys were harvested. Given previous studies showing HBMSC-EV hepatic uptake after IV injection, the liver was evaluated for changes in inflammation, fibrosis, and proliferation. Results: On postoperative day 28, there were no significant differences in left ventricular ejection fraction (P = 0.6151), fractional shortening (P = 0.1135), or anterior border zone fibrosis (P = 0.6333) in any of the experimental groups. Interestingly, there was a strong trend demonstrating improvement in infarct size on fibrosis staining, which did not reach significance (P = 0.05620). There were no differences in hepatic inflammation, fibrosis, and proliferation. Conclusions: Although there was a trend in the improvement in infarct size, a single-dose administration of neither IM nor IV injection of HBMSC-EV resulted in significant improvement in post-MI cardiac function. A major limitation of this study is the lack of trials determining the optimal dose of HBMSC-EV needed in this model. However, the current study demonstrates that future studies are required to either optimize administration or bioengineer HBMSC-EV with cardiac-homing properties.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lack of cardiac benefit after intramyocardial or intravenous injection of mesenchymal stem cell-derived extracellular vesicles supports the need for optimized cardiac delivery

Xu,

Broadwin,

Faherty

et al. 2023

Vessel Plus

View full text Add to dashboard Cite

show abstract

“…These exosomes can be isolated from the culture media of these cells and then administered to the liver. Furthermore, exosomes can transfer various bioactive molecules, such as growth factors, cytokines, and microRNAs, to recipient cells in the liver 112 . These molecules can regulate gene expression, promote cell survival, and modulate the immune response, which is essential for hepatic regeneration 113 .…”

Section: Applications Of Exosome-loaded Biomaterialsmentioning

confidence: 99%

Engineered exosomes and composite biomaterials for tissue regeneration

Hu,

Wang,

Chen

et al. 2024

Theranostics

View full text Add to dashboard Cite

Exosomes, which are small vesicles enclosed by a lipid bilayer and released by many cell types, are widely dispersed and have garnered increased attention in the field of regenerative medicine due to their ability to serve as indicators of diseases and agents with therapeutic potential. Exosomes play a crucial role in mediating intercellular communication through the transfer of many biomolecules, including proteins, lipids, RNA, and other molecular constituents, between cells. The targeted transport of proteins and nucleic acids to specific cells has the potential to enhance or impair specific biological functions. Exosomes have many applications, and they can be used alone or in combination with other therapeutic approaches. The examination of the unique attributes and many functions of these factors has emerged as a prominent field of study in the realm of biomedical research. This manuscript summarizes the origins and properties of exosomes, including their structural, biological, physical, and chemical aspects. This paper offers a complete examination of recent progress in tissue repair and regenerative medicine, emphasizing the possible implications of these methods in forthcoming tissue regeneration attempts.

show abstract

“… 47 Noncoding RNAs in exosomes have been shown to play a therapeutic role in a variety of liver diseases by inhibiting inflammatory response, alleviating oxidative stress in the liver, and inhibiting the activation and proliferation of hepatic stellate cells. 48 …”

Section: Introductionmentioning

confidence: 99%

Current Status and Prospect of Delivery Vehicle Based on Mesenchymal Stem Cell-Derived Exosomes in Liver Diseases

Lu¹,

Guo²,

Wei³

et al. 2023

IJN

View full text Add to dashboard Cite

With the improvement of the average life expectancy and increasing incidence of obesity, the burden of liver disease is increasing. Liver disease is a serious threat to human health. Currently, liver transplantation is the only effective treatment for end-stage liver disease. However, liver transplantation still faces unavoidable difficulties. Mesenchymal stem cells (MSCs) can be used as an alternative therapy for liver disease, especially liver cirrhosis, liver failure, and liver transplantation complications. However, MSCs may have potential tumorigenic effects. Exosomes derived from MSCs (MSC-Exos), as the important intercellular communication mode of MSCs, contain various proteins, nucleic acids, and DNA. MSC-Exos can be used as a delivery system to treat liver diseases through immune regulation, apoptosis inhibition, regeneration promotion, drug delivery, and other ways. Good histocompatibility and material exchangeability make MSC-Exos a new treatment for liver diseases. This review summarizes the latest research on MSC-Exos as delivery vehicles in different liver diseases, including liver injury, liver failure, liver fibrosis, hepatocellular carcinoma (HCC), and ischemia and reperfusion injury. In addition, we discuss the advantages, disadvantages, and clinical application prospects of MSC-Exos-based delivery vectors in the treatment of liver diseases.

show abstract

Mesenchymal stem cell-derived exosomes and non-coding RNAs: Regulatory and therapeutic role in liver diseases

Cited by 12 publications

References 165 publications

Lack of cardiac benefit after intramyocardial or intravenous injection of mesenchymal stem cell-derived extracellular vesicles supports the need for optimized cardiac delivery

Lack of cardiac benefit after intramyocardial or intravenous injection of mesenchymal stem cell-derived extracellular vesicles supports the need for optimized cardiac delivery

Engineered exosomes and composite biomaterials for tissue regeneration

Current Status and Prospect of Delivery Vehicle Based on Mesenchymal Stem Cell-Derived Exosomes in Liver Diseases

Contact Info

Product

Resources

About